for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

IDEXX Laboratories, Inc.

IDXX.OQ

Latest Trade

384.83USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

168.75

 - 

407.25

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
384.83
Open
--
Volume
--
3M AVG Volume
10.61
Today's High
--
Today's Low
--
52 Week High
407.25
52 Week Low
168.75
Shares Out (MIL)
85.05
Market Cap (MIL)
31,813.00
Forward P/E
76.36
Dividend (Yield %)
--

Next Event

IDEXX Laboratories Inc Investor Day 2020

Latest Developments

More

Idexx Laboratories Announces Q2 Earnings Per Share $1.72

Idexx Laboratories Enters Into Second Amendment To Multicurrency Note Purchase & Private Shelf Agreement

Idexx Laboratories Announces Increase In Share Repurchase Program Authorization

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its segments include diagnostic and information technology-based products and services for the veterinary market, which the Company refers to as the Companion Animal Group; water quality products; diagnostic products and services for livestock and poultry health, which the Company refers to as Livestock, Poultry and Dairy, and Other operating segment, which combines and presents products for the human point-of-care medical diagnostics market with its pharmaceutical product line and its out-licensing arrangements. Its products and services include point-of-care veterinary diagnostic products, comprising instruments, consumables and rapid assay test kits, among others.

Industry

Fish/Livestock

Contact Info

1 Idexx Dr

WESTBROOK, ME

04092-2041

United States

+1.207.5560300

https://www.idexx.com/

Executive Leadership

Lawrence D. Kingsley

Independent Chairman of the Board

Jonathan Mazelsky

President, Chief Executive Officer, Director

Brian P. McKeon

Chief Financial Officer, Executive Vice President, Treasurer

Giovani Twigge

Chief Human Resource Officer, Corporate Vice President

Tina Hunt

Executive Vice President, General Manager, Point of Care Diagnostics and Worldwide Operations

Key Stats

2.00 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

2.0K

2018

2.2K

2019

2.4K

2020(E)

2.6K
EPS (USD)

2017

3.280

2018

4.260

2019

4.890

2020(E)

5.656
Price To Earnings (TTM)
70.68
Price To Sales (TTM)
12.86
Price To Book (MRQ)
116.54
Price To Cash Flow (TTM)
57.63
Total Debt To Equity (MRQ)
337.37
LT Debt To Equity (MRQ)
292.82
Return on Investment (TTM)
36.46
Return on Equity (TTM)
24.98

Latest News

Latest News

IDEXX Labs launches COVID-19 test for pets amid rare cases of human-to-pet transmission

IDEXX Laboratories Inc said on Monday it would provide veterinarians a COVID-19 test for pets amid evidence that infected humans could transmit the virus to their pets.

BRIEF-Idexx Makes Pet Test For COVID-19 Virus Available To Veterinarians

* IDEXX MAKES PET TEST FOR COVID-19 VIRUS AVAILABLE TO VETERINARIANS

BRIEF-IDEXX Laboratories Inc Enters Second Amendment To Note Purchase And Private Shelf Agreement

* IDEXX LABORATORIES INC - ON APRIL 10, 2020, COMPANY ENTERED INTO SECOND AMENDMENT TO NOTE PURCHASE AND PRIVATE SHELF AGREEMENT

BRIEF-Idexx Laboratories Enters Into Second Amendment To Multicurrency Note Purchase & Private Shelf Agreement

* IDEXX LABORATORIES - ON MARCH 23, CO ENTERED INTO SECOND AMENDMENT TO MULTICURRENCY NOTE PURCHASE & PRIVATE SHELF AGREEMENT

BRIEF-Leading Veterinary Diagnostic Company Sees No Covid-19 Cases In Pets

* LEADING VETERINARY DIAGNOSTIC COMPANY SEES NO COVID-19 CASES IN PETS

BRIEF-Idexx Laboratories Announces Increase In Share Repurchase Program Authorization

* IDEXX LABORATORIES ANNOUNCES INCREASE IN SHARE REPURCHASE PROGRAM AUTHORIZATION

BRIEF-Idexx Laboratories Reports Q1 Earnings Per Share $1.01

* Q1 EARNINGS PER SHARE VIEW $0.92 -- THOMSON REUTERS I/B/E/S

BRIEF-IDEXX Laboratories Reports Q4 Earnings Per Share $0.43

* IDEXX LABORATORIES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 RESULTS

BRIEF-IDEXX To Introduce Applied Biocode's Innovative Multiplex Technology Across Global Reference Laboratory Network

* IDEXX TO INTRODUCE APPLIED BIOCODE'S INNOVATIVE MULTIPLEX TECHNOLOGY ACROSS GLOBAL REFERENCE LABORATORY NETWORK

BRIEF-Idexx Laboratories Announces Estimated Impact Of U.S. Tax Reform

* IDEXX LABORATORIES ANNOUNCES ESTIMATED IMPACT OF U.S. TAX REFORM

BRIEF-IDEXX Laboratories Q3 earnings per share $0.79

* Q3 earnings per share view $0.74 -- Thomson Reuters I/B/E/S

BRIEF-Idexx Laboratories reports Q2 EPS $0.95

* Sees fy 2017 earnings per share $3.12 to $3.22 including items

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up